What to know about the COVID-19 variant that may cause ‘razor blade' sore throats
Experts say there isn't major cause for concern with the Nimbus variant, but here 's what else you need to know about it.
Here's where the variant causing 'razor blade throat' spreading
The rise in cases late last month is primarily in eastern Mediterranean, Southeast Asia and western Pacific regions, the World Health Organization said May 28. The new variant had reached nearly 11% of sequenced samples reported globally in mid-May.
Advertisement
Airport screening in the United States detected the new variant in travelers arriving from those regions to destinations in California, Washington state, Virginia and New York.
You aren't likely to get sicker from this variant than others
Not so far, anyway.
The WHO said some western Pacific countries have reported increases in COVID cases and hospitalizations, but there's nothing so far to suggest that the disease associated with the new variant is more severe compared to other variants.
COVID-19 vaccines are effective against the Nimbus variant
Yes.
The WHO has designated Nimbus as a 'variant under monitoring' and considers the public health risk low at the global level. Current vaccines are expected to remain effective.
Health Secretary Robert F. Kennedy Jr. announced last month that COVID-19 shots are no longer recommended for healthy children and pregnant women — a move immediately questioned by public health experts.
Advertisement
AP Health Writer Carla Johnson contributed to this story.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
16 minutes ago
- The Hill
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it
WASHINGTON (AP) — The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said 'gaping holes in the system' in the U.S. and globally 'are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' twice a year to keep up their protection. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. People must test negative for HIV before getting their twice-a-year dose, Gilead warned. It only prevents HIV transmission — it doesn't block other sexually transmitted diseases. Some researchers who helped test the shot advise cold packs to counter injection-site pain. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' Gilead said the U.S. list price, meaning before insurance, is $28,218 a year, which it called similar to some other PrEP options. The company said it anticipated insurance coverage but also has some financial assistance programs. Most private insurers are supposed to cover PrEP options without a co-pay although the Supreme Court is considering a case that could overturn that requirement. Congress also is considering huge cuts to Medicaid. And while community health centers still are an option, the Trump administration has largely dismantled HIV prevention work at the Centers for Disease Control and Prevention that would normally get the message to vulnerable populations who'd qualify for the shot, said Carl Schmid of the nonprofit HIV+Hepatitis Policy Institute. Schmid worries the shot won't meet its potential because 'we're basically pulling the rug out of HIV prevention and testing and outreach programs.' Gilead also has applications pending for the twice-yearly shot in other countries. Last fall, the company signed agreements with six generic drug makers to produce low-cost versions of the shot for 120 poor countries mostly in Africa, Southeast Asia and the Caribbean. Gilead plans to make enough shots to supply 2 million people in those countries, at no profit, until the generics are available, said company senior vice president Dr. Jared Baeten. Winnie Byanyima, executive director of UNAIDS, said in a statement the price is still too high. If it's unaffordable, she said, 'it will change nothing.' And HIV experts worry the arrangements Gilead has made to reduce costs in some countries leave out middle-income countries like some in Latin America. 'Everyone in every country who's at risk of HIV needs access to PrEP,' said Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
an hour ago
New CDC advisers will skip some expected topics and explore a target of antivaccine activists
U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisers meet next week, but their agenda suggests they'll skip some expected topics — including a vote on COVID-19 shots — while taking up a longtime target of anti-vaccine groups. The Advisory Committee on Immunization Practices makes recommendations on how to use the nation's vaccines, setting a schedule for children's vaccines as well as advice for adult shots. Last week, Kennedy abruptly dismissed the existing 17-member expert panel and handpicked eight replacements, including several anti-vaccine voices. The agenda for the new committee's first meeting, posted Wednesday, shows it will be shorter than expected. Discussion of COVID-19 shots will open the session, but the agenda lists no vote on that. Instead, the committee will vote on fall flu vaccinations, on RSV vaccinations for pregnant women and children and on the use of a preservative named thimerosal that's in a subset of flu shots. It's not clear who wrote the agenda. No committee chairperson has been named and the U.S. Department of Health and Human Services did not comment. Missing from the agenda are some heavily researched vaccine policy proposals the advisers were supposed to consider this month, including shots against HPV and meningococcal bacteria, said Dr. Susan Kressly, president of the American Academy of Pediatrics. Instead, the committee is talking about subjects 'which are settled science,' she said. 'Every American should be asking themselves how and why did we get here, where leaders are promoting their own agenda instead of protecting our people and our communities,' she said. She worried it's "part of a purposeful agenda to insert dangerous and harmful and unnecessary fear regarding vaccines into the process.' The committee makes recommendations on how vaccines that have been approved by the Food and Drug Administration should be used. The recommendations traditionally go to the Centers for Disease Control and Prevention director. Historically, nearly all are accepted and then used by insurance companies in deciding what vaccines to cover. But the CDC has no director and the committee's recommendations have been going to Kennedy. Thimerosal was added to certain vaccines in the early 20th century to make them safer and more accessible by preventing bacterial contamination in multi-dose vials. It's a tiny amount, but because it's a form of mercury, it began raising questions in the 1990s. Kennedy — a leading voice in an antivaccine movement before he became President Donald Trump's health secretary — has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Study after study has found no evidence that thimerosal causes autism. But since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Thimerosal now only appears in multidose flu shot vials, not the single-shot packaging of most of today's flu shots. Targeting thimerosal would likely force manufacturers to switch to single-dose vials, which would make the shots 'more expensive, less available and more feared,' said Paul Offit, a vaccine expert at Children's Hospital of Philadelphia. Last week, 30 organizations called on insurers to continue paying for COVID-19 vaccines for pregnant women after Kennedy said the shots would no longer be routinely recommended for that group. Doctors' groups also opposed Kennedy's changes to the vaccine committee. The new members he picked include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a top critic of pandemic-era lockdowns and a leader of a group that has been widely considered to be a source of vaccine misinformation. The American Academy of Pediatrics has long put out its own immunization recommendations. In recent decades it has matched what the government recommended. But asked if they might soon diverge, depending on potential changes in the government's vaccination recommendations, Kressly said; 'Nothing's off the table.' 'We will do whatever is necessary to make sure that every child in every community gets the vaccines that they deserve to stay healthy and safe,' she said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
The world's only twice-a-year shot to prevent HIV could stop transmission -- if people can get it
WASHINGTON (AP) — The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said 'gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' twice a year to keep up their protection. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. People must test negative for HIV before getting their twice-a-year dose, Gilead warned. It only prevents HIV transmission — it doesn't block other sexually transmitted diseases. Some researchers who helped test the shot advise cold packs to counter injection-site pain. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' Gilead said the U.S. list price, meaning before insurance, is $28,218 a year, which it called similar to some other PrEP options. The company said it anticipated insurance coverage but also has some financial assistance programs. Most private insurers are supposed to cover PrEP options without a co-pay although the Supreme Court is considering a case that could overturn that requirement. Congress also is considering huge cuts to Medicaid. And while community health centers still are an option, the Trump administration has largely dismantled HIV prevention work at the Centers for Disease Control and Prevention that would normally get the message to vulnerable populations who'd qualify for the shot, said Carl Schmid of the nonprofit HIV+Hepatitis Policy Institute. Schmid worries the shot won't meet its potential because 'we're basically pulling the rug out of HIV prevention and testing and outreach programs.' Gilead also has applications pending for the twice-yearly shot in other countries. Last fall, the company signed agreements with six generic drug makers to produce low-cost versions of the shot for 120 poor countries mostly in Africa, Southeast Asia and the Caribbean. Gilead plans to make enough shots to supply 2 million people in those countries, at no profit, until the generics are available, said company senior vice president Dr. Jared Baeten. Winnie Byanyima, executive director of UNAIDS, said in a statement the price is still too high. If it's unaffordable, she said, 'it will change nothing.' And HIV experts worry the arrangements Gilead has made to reduce costs in some countries leave out middle-income countries like some in Latin America. 'Everyone in every country who's at risk of HIV needs access to PrEP,' said Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.'
